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Volume xAvailable online XXXBackground: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2
(gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple
negative breast cancer (TNBC) wild type for BRCA1/2, we hypothesized that PARPi may be effective in primary TNBCs
without previous chemotherapy exposure.
Patients and methods: In the phase II PETREMAC trial, patients with primary TNBC >2 cm received olaparib for up to
10 weeks before chemotherapy. Tumor biopsies collected before and after olaparib underwent targeted DNA
sequencing (360 genes) and BRCA1 methylation analyses. In addition, BRCAness (multiplex ligation-dependent probe
amplification), PAM50 gene expression, RAD51 foci, tumor-infiltrating lymphocytes (TILs) and PD-L1 analyses were
performed on pretreatment samples.
Results: The median pretreatment tumor diameter was 60 mm (range 25-112 mm). Eighteen out of 32 patients
obtained an objective response (OR) to olaparib (56.3%). Somatic or germline mutations affecting homologous
recombination (HR) were observed in 10/18 responders [OR 55.6%, 95% confidence interval (CI) 33.7-75.4]
contrasting 1/14 non-responders (OR 7.1%; CI 1.3-31.5, P ¼ 0.008). Among tumors without HR mutations, 6/8
responders versus 3/13 non-responders revealed BRCA1 hypermethylation (P ¼ 0.03). Thus, 16/18 responders
(88.9%, CI 67.2-96.9), in contrast to 4/14 non-responders (28.6%, CI 11.7-54.7, P ¼ 0.0008), carried HR mutations
and/or BRCA1 methylation. Excluding one gPALB2 and four gBRCA1/2 mutation carriers, 12/14 responders (85.7%,
CI 60.1-96.0) versus 3/13 non-responders (23.1%, CI 8.2-50.3, P ¼ 0.002) carried somatic HR mutations and/or
BRCA1 methylation. In contrast to BRCAness signature or basal-like subtype, low RAD51 scores, high TIL or high PD-
L1 expression all correlated to olaparib response.
Conclusion: Olaparib yielded a high clinical response rate in treatment-naïve TNBCs revealing HR deficiency, beyond
germline HR mutations.
Trial registration: ClinicalTrials.gov identifier: NCT02624973.
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Triple negative breast cancer (TNBC) is a breast cancer sub-
group defined by lack of estrogen receptors (ER) and pro-
gesterone receptors (PGR) (ER/PGR negative) and normal
HER2 protein expression. TNBC constitutes approximately
15% of all breast cancers,1,2 and despite high response rates
to chemotherapy, these patients have a poor prognosis
compared to patients with other breast cancer subtypes.2-4
While early evidence indicates a potential role for immune
checkpoint inhibition in selected TNBC, so far no overall
survival gain has been observed either in early or metastatic
disease.5,6 Thus, as of today there are no targeted therapies
with a definite role in primary TNBC.
While about 15% of unselected TNBC harbor BRCA1 germ-
line (gBRCA1) mutations,7 the majority of TNBCs reveal a gene
expression signature mirroring that observed in gBRCA1 mu-
tation carriers.1,8Moreover,TNBCsmay harbor somatic BRCA1
mutations, BRCA1 silencing through promoter hyper-
methylation, or somatic/germline alterations affecting other
genes related to homologous recombination (HR).7,9 Thus, HR
deficiency (HRD), defined by somatic or germline HR muta-
tions, BRCA1 methylation or different genomic or gene
expression signatures, is observed in 50%-80%of TNBCs.7-10Of
note, BRCA1 methylated and gBRCA1 mutated TNBCs share
gene expression and immune profiles, and seem to have a
similar outcome after adjuvant chemotherapy,11 indicating
that somaticHRDmay promote the samebiological phenotype
and treatment response as germline HRD in TNBC.
PARP inhibitors (PARPi) impair base excision repair (BER)
through direct PARP inhibition and by trapping the PARP1
complex to DNA, subsequently causing double-strand
breaks (DSB).12 Thus, PARPi are selectively cytotoxic to
cells carrying defects in DSB repair due to HR defects by
synthetic lethality.13,14 Among breast cancer patients car-
rying gBRCA1/2 mutations, PARPi has been shown to pro-
long progression-free survival in metastatic, HER2-negative
disease,15-19 but also to induce profound tumor shrinkage
in the neoadjuvant setting.20 However, no benefit was
recorded among patients with metastatic TNBC not
harboring gBRCA mutations.17 Notably, secondary reverting
mutations arising during platinum therapy may restore
BRCA1/2 function and are associated with resistance to
subsequent platinum or PARP inhibitor treatment in pa-
tients with breast and ovarian cancer.12,21-23 If treatment
with DNA crosslinking agents, such as carboplatin or
cyclophosphamide, induces resistance to PARP inhibitors,
this could explain the lack of benefit from olaparib observed
in patients with late-stage metastatic breast cancer.17
Interestingly, PARPi was beneficial to patients with heavily
pretreated metastatic prostate cancer,24,25 a patient group
typically not exposed to crosslinking agents.
Platinum compounds mediate DSB through DNA cross-
linking and are of increased efficacy among gBRCA1/2 mu-
tation carriers with metastatic TNBC.26 Furthermore,
platinum compounds could be of particular benefit in primary
TNBC if germline or somatic HR defects are present, although2 https://doi.org/10.1016/j.annonc.2020.11.009the results are at variance.27,28 While combined platinum-
based chemotherapy and PARP inhibition with veliparib
improved progression-free survival in gBRCA1/2 mutated,
advanced breast cancer compared with chemotherapy
alone,29 the benefit from such combined regimens in TNBC
without gBRCA1/2 mutations is less clear.30,31 Considering
other PARP inhibitors, such as olaparib or talazoparib, which
exhibit stronger PARP trapping activity than veliparib,12 the
therapeutic window for administering them in concert with
platinum compounds is narrowed by bone marrow
toxicity.32,33 However, olaparib and talazoparib are effective
as monotherapy in advanced breast cancer among patients
harboring gBRCA1/2 and gPALB2mutations.13,16,19,20,34 Thus,
an alternative approach could be to apply a PARPi with potent
PARP trapping activity and chemotherapy sequentially in the
neoadjuvant setting.
Based on the evidence above, we hypothesized that PARP
inhibition could be effective in treatment-naïve TNBC,
beyond BRCA1/2 germline defects. Here, we report the
clinical efficacy of olaparib monotherapy before chemo-
therapy for unselected TNBC in the neoadjuvant PETREMAC
trial (Clinicaltrials.gov #NCT02624973) with predictive
markers identifying patients likely to benefit from such
treatment.
PATIENTS AND METHODS
Study design and patients
In the phase II PETREMAC trial, patientswith stage II/III breast
cancer (American Joint Committee on Cancer, Breast Cancer
Staging, 7th edition, CancerStaging.org) were stratified to
eight different neoadjuvant treatment regimens based on ER,
PGR and HER2 expression as well as TP53 mutation status
(Figure 1). The primary aim of the trial was to implement
optimal neoadjuvant therapy for high-risk breast cancers,
select therapy based on predefined biological parameters
and identify novel predictive biomarkers for each individual
treatment strategy. Patients with TNBC received initial ola-
parib monotherapy 300 mg b.i.d. for up to 10 weeks, irre-
spective of BRCA and TP53 mutation status (treatment arms
G and H; Figure 1), aiming to shrink tumor size before
chemotherapy. Olaparib monotherapy was halted and
chemotherapy was introduced before 10 weeks for patients
without evidence of tumor regression (Table 1). Chemo-
therapy regimens tested after initial olaparib monotherapy
are described in Figure 1 and in supplementary Methods,
available at https://doi.org/10.1016/j.annonc2020.11.009.
Clinical and radiological evaluation of tumor size was carried
out by each local investigator, blinded to knowledge of
genomic aberrations, apart from TP53 mutation status.
DNA and RNA analyses
Pre-planned targeted DNA sequencing applying a 360-gene
panel35 was conducted on tumor biopsies extracted
before and after olaparib treatment, as described in
supplementary Methods, available at https://doi.org/10.Volume xxx - Issue xxx - 2020
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Figure 1. Outline of study arms of the neoadjuvant PETREMAC trial (A).
After informed consent, breast cancer biopsies were taken and examined for estrogen receptor (ER), progesterone receptor (PGR) and HER2 expression, in addition to
TP53 mutation status during the screening phase. Based on these results, patients were allocated to the eight study arms to receive personalized neoadjuvant treatment
of large T2 (T >4 cm) or locally advanced breast cancers. Patients with triple negative breast cancer (TNBC) were allocated to study arms G (TP53 wildtype; TP53 wt) and
H (TP53 mutated tumor; TP53 mut) and received initial olaparib monotherapy (PARP inhibitor; PARPi) with or without subsequent chemotherapy with the aim of an
objective response. Due to inadequate tumor regression observed in the initial eight patients in arms G and H (Outline A), the protocol was amended to change the
chemotherapy given after the initial olaparib monotherapy phase (Outline B). Chemotherapy changes are marked by orange boxes. Also, the amendment allowed for
inclusion of tumors >2 cm in arms E, F, G and H.
AI, aromatase inhibitor; cyclophosph., cyclophosphamide; ER, estrogen receptor; mut, mutation; wks, weeks; wt, wildtype.
H. P. Eikesdal et al. Annals of Oncology1016/j.annonc2020.11.009. Mutations identified were an-
notated as likely drivers, involved in HR or other DNA damage
repair pathways, by predefined criteria (supplementary
Table S1, available at https://doi.org/10.1016/j.annonc202
0.11.009). Further, pre-planned analyses of tumor samples
for BRCA1 promoter methylation by methylation-specificVolume xxx - Issue xxx - 2020quantitative PCR and BRCAness by multiplex ligation-
dependent probe amplification (MLPA) were carried out
(see supplementary Methods, available at https://doi.org/1
0.1016/j.annonc2020.11.009). A post-hoc gene expression
analysis was carried out on pretreatment biopsies to assign
all tumors to a PAM50 breast cancer subgroup (seehttps://doi.org/10.1016/j.annonc.2020.11.009 3
Table 1. Patient characteristics and response to olaparib monotherapy for triple negative breast cancers in the PETREMAC trial
ID Study arm T N Age Response to olapariba Olaparib
(weeks)d
1. Clinical measurement (caliper)b 2. MRI breastb 1 þ 2c
TND before TND after % change RECIST TND before TND after % Change RECIST
1 G 2 0 37 35 0 100 CR 24 0 100 CR CR 10
2 H 3 0 61 56 36 36 PR 75 39 48 PR PR 10
3 G 3 0 49 70 20 71 PR 36 18 50 PR PR 10
4 H 2 0 68 28 0 100 CR 29 17 41 PR PR 10
5 H 3 0 42 56 30 46 PR 30 19 37 PR PR 10
6 H 3 0 72 70 50 29 SD 33 23 30 PR PR 10
7 H 3 3 46 73 30 59 PR 86 NMe NM PR PR 10
8 H 3 0 46 62 33 47 PR 42 15 64 PR PR 10
9 H 3 0 35 60 0 100 CR 38 23 39 PR PR 10
10 H 2 0 34 45 20 56 PR 80 37 54 PR PR 10
11 H 3 0 57 68 45 34 PR 45 21 53 PR PR 10
12 G 3 2 72 75 55 27 SD 49 34 31 PR PR 10
13 G 3 0 45 80 40 50 PR 73 NMe NM PR PR 10
14 H 2 0 72 50 0 100 CR 67 21 69 PR PR 10
15 H 3 0 41 80 40 50 PR 56 28 50 PR PR 10
16 H 2 0 42 35 15 57 PR 28 14 50 PR PR 10
17 H 3 0 45 76 30 61 PR 76 30 61 PR PR 10
18 H 2 0 67 44 32 27 SD 42 15 64 PR PR 10
19 H 3 0 60 53 40 25 SD 45 41 9 SD SD 10f
20 H 2 0 40 47 37 21 SD 19 25 31 PDg SD 10
21 H 3 1 60 82 65 21 SD 60 48 20 SD SD 6
22 H 2 0 45 50 56 12 SD 24 25 4 SD SD 10
23 H 3 0 36 60 60 0 SD 105 95 10 SD SD 8
24 G 3 0 56 60 40 33 PR 93 90 3 SD SD 10
25 H 3 1 28 112 74 34 PR 107 98 9 SD SD 10
26 G 3 0 66 55 45 18 SD 50 50 0 SD SD 10
27 H 2 0 42 50 45 10 SD 40 41 3 SD SD 4
28 H 0h 2 58 25i NAj NA 39 31 21 SDk SD 7
29 H 2 2 65 70 55 21 SD 32 NAi NA SD 6
30 G 3 0 64 70 75 7 SD 60 80 33 PD PD 7
31 G 3 0 65 54 45 17 SD 37 45 22 PD PD 6
32 H 3 0 46 55 20 64 PR 38 42 11 PDl PD 10
ID: Patient study ID.
Study arm: G; TNBC; TP53 wildtype. H; TNBC, TP53 mutated.
T and N: tumor and nodal stage (TNM guidelines (American Joint Committee on Cancer, Breast Cancer Staging, 7th edition, CancerStaging.org)).
Age: Patient’s age in years at diagnosis.
TND: tumor and nodal diameter, i.e. combined tumor diameter (longest) and nodal metastasis diameter (shortest).
CR, complete response; NA, not assessed; NM, not measurable; PD, progressive disease; PR, partial response SD, stable disease.
a Assessment by local principal investigator and radiologist.
b Size in millimeter; T and N size combined. Median pretreatment tumor diameter (clinical measurements) 60 mm for olaparib responders (CR þ PR) versus 55 mm for non-
responders (SD). Median pretreatment tumor diameter (MRI measurements) 44 mm for olaparib responders (CR þ PR) versus 45 mm for non-responders (SD).
c Combined response assessment based on clinical and breast MRI evaluation per RECIST1.1. MRI response dictated the combined response, apart from patients 20 and 29 where
clinical caliper measurements were used. For patient 29 an MRI had not been performed after olaparib treatment and for patient 20 the MRI result after olaparib was ambiguous.
See footnote g.
d Olaparib therapy (tablets 300 mg BID) was pre-planned for 10 weeks, but at the discretion of the local principal investigator chemotherapy was introduced earlier if tumor
regression on olaparib was not observed.
e NM: non-measurable tumor remnants described by the radiologist in the breast MRI exam, i.e. remaining tumor tissue is suspected, but can no longer be measured due to
profound tumor regression.
f Patient withdrawn from trial after olaparib due to retrospective diagnosis of pre-treatment M1 disease.
g Diameter increase due to tumor core liquefaction/central necrosis.
h Prior mastectomy; inclusion failure, included in intention-to-treat analysis.
i Axillary recurrence; short diameter.
j NA: not assessed (protocol violation).
k Computer tomography (CT) evaluation at 4 weeks.
l PD due to cN1 (cN0 axilla pre-treatment).
Annals of Oncology H. P. Eikesdal et al.supplementary Methods, available at https://doi.org/10.1
016/j.annonc2020.11.009).Immunostaining procedures and tumor-infiltrating
lymphocytes
Immunostaining for RAD51, BRCA1 and PD-L1 and quanti-
fication of immunostaining and tumor-infiltrating lympho-
cytes (TILs) are outlined in supplementary Methods4 https://doi.org/10.1016/j.annonc.2020.11.009(available at https://doi.org/10.1016/j.annonc2020.11.009).
These were post-hoc assessments to examine the immune
status as well as HR function in the tumors.Ethics and approvals
The study protocol and clinical trial set-up were approved by
the Regional Ethical Committee of the Western health region
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Figure 2. OncoPrint list of mutations in homologous recombination genes in triple negative breast cancers (TNBC, N [ 32) from the PETREMAC trial.
HR mutations were recorded before and after initial olaparib monotherapy (4-10 weeks treatment), using targeted DNA sequencing (360-gene panel). The mutation list
is sorted by olaparib response, and mutations are color-coded based on type of mutation detected. Genes are listed on the left; the letter ‘g’ before gene names
designates germline mutations. Percentages and bars on the right indicate the prevalence of each mutation that was identified among the 32 tumors analyzed. Patient
IDs are given below the columns; each column represents one tumor and one patient. Box diagrams summarize the presence of HR mutations and BRCA1 methylation
before and after olaparib, the presence of a BRCAness signature and PAM50 breast cancer subtypes in pretreatment tumor samples, as well as response to olaparib.
Response to olaparib was a combined assessment, clinically and by breast MRI, per RECIST1.1 guidelines. Tumors with a BRCA1-like profile by multiplex ligation-
dependent probe amplification (MLPA) analysis were defined as having a BRCAness signature.
*Only pretreatment biopsy available for Patient 19.
**Indicates analyses of pretreatment tumor biopsies.
CR, complete response; HR, homologous recombination; PD, progressive disease; PR, partial response; SD, stable disease.
H. P. Eikesdal et al. Annals of Oncology(#2015/8463) and was registered at Clinicaltrials.gov
(NCT02624973) and with EudraCT (#2015-002816-34). The
study was conducted in accordance with the protocol, good
clinical practice guidelines, provisions of the Declaration of
Helsinki and all local regulations. All patients signed informed
consent before inclusion.
Statistics
All statistical analyses were carried out using R, version
3.5.3, or the SPSS 15.0/PASW 17.0 software package (SPSS
Inc.). Statistical methods and confidence interval calcula-
tions are described in detail in supplementary Methods,
available at https://doi.org/10.1016/j.annonc2020.11.009.
All P values reported are two-tailed. No P value was cor-
rected for multiple testing. However, as HR mutations andVolume xxx - Issue xxx - 2020BRCA1 methylation status were considered independent
predictors of response, the P value threshold for statistical
significance was set at <0.025 when these two factors were
combined.RESULTS
Out of 222 patients screened for trial participation, 203
commenced and 200 patients completed neoadjuvant
treatment in the PETREMAC trial (CONSORT diagram;
supplementary Figure S1, available at https://doi.org/10.
1016/j.annonc2020.11.009). Thirty-two patients with TNBC
(median longest tumor diameter 60 mm; range 25-112 mm)
received initial olaparib monotherapy (4-10 weeks) in
treatment arms G/H (Figure 1), underwent clinical andhttps://doi.org/10.1016/j.annonc.2020.11.009 5
Table 2. Statistical comparison of homologous recombination deficiency parameters among olaparib response groups.
Subgroup HR deficiency CR D PRa SD PD P value trend P value
Fisher’s exactb
All patients HR mutationc positive 10 1 0 0.006 0.008
Negative 8 10 3
Total 18 11 3
gBRCA/gPALB2 wt HR mutation positive 6 0 0 0.02 0.02
Negative 8 10 3
Total 14 10 3
No HR mutation BRCA1 methylation positive 6 1 2 0.2 0.03
Negative 2 9 1
Total 8 10 3
All patients HR mutation and/or BRCA1 methylation positived 16 2 2 0.01 0.0008
Negative 2 9 1
Total 18 11 3
gBRCA/gPALB2 wt HR mutation and/or BRCA1 methylation positived 12 1 2 0.03 0.002
Negative 2 9 1
Total 14 10 3
All patients BRCAness signature positivee 13 4 1 0.05 0.07
Negative 5 7 2
Total 18 11 3
Combined clinical and MRI evaluation (N ¼ 32).
CR, complete response; HR, homologous recombination; PD, progressive disease; PR, partial response; SD, stable disease.
a CR and PR groups combined since there was only one CR.
b CR/PR versus SD/PD.
c HR mutations: ATRX, BRCA1/2, EMSY, MEN1, PALB2, PTEN, SETD2.
d Combined HR mutation and BRCA1 methylation: N ¼ 2; Patients #5 and #8.
e BRCAness signature positive ¼ BRCA1-like profile by Multiplex Ligation-dependent Probe Amplification (MLPA).
Annals of Oncology H. P. Eikesdal et al.breast MRI evaluation (Table 1) per protocol and were
included in the intention-to-treat analysis.
Responses to olaparib are detailed for individual patients in
Table 1 and depicted aswaterfall plots for clinical (caliper) and
MRI evaluation per RECIST1.1 in supplementary Figures S2
and S3 (available at https://doi.org/10.1016/j.annonc2020.
11.009). A combined clinical and MRI response to olaparib
was scored for each patient, where the response categorywas
dictated by the MRI evaluation, unlessMRI data were missing
or ambiguous (two patients; details in Table 1). Based on
combined clinical and MRI evaluation, olaparib treatment
yielded one clinical complete response and 17 partial re-
sponses from32 patients [objective response rate; ORR 56.3%
(CI 39.3-71.8)]. Response to olaparib occurred independent
of tumor size (Table 1). Importantly, excluding patients
harboring gBRCA1/2 (n¼ 4) and gPALB2 (n¼ 1)mutations, an
objective responsewas recorded in 14 out of 27 patients (ORR
51.9%, CI 34.0-69.3, Figure 2). Olaparibmonotherapywaswell
tolerated, with only one patient experiencing >grade 2
toxicity (fatigue; scored using Common Terminology Criteria
for Adverse Events, CTCAE, version 4.03) and requiring a dose
reduction (supplementary Table S2, available at https://doi.
org/10.1016/j.annonc2020.11.009).
Statistical comparisons of HR deficiency parameters (HR
mutations and BRCA1 methylation) between olaparib re-
sponders and non-responders are summarized in Table 2 for
combined clinical and MRI evaluation, whereas statistics
based on either clinical or MRI evaluations are listed
separately in supplementary Table S3, available at https://
doi.org/10.1016/j.annonc2020.11.009.
Pathogenic germline (BRCA1/2 and PALB2) or somatic
(ATRX, BRCA1, EMSY, MEN1, PTEN, SETD2) mutations6 https://doi.org/10.1016/j.annonc.2020.11.009affecting genes involved in HR were present in 10 out of 18
responders (OR 55.6%, CI 33.7-75.4), contrasting 1 out of 14
non-responders (OR 7.1%, CI 0.0-31.5, P ¼ 0.008, Figure 2
and Table 2). Excluding all five patients harboring
gBRCA1/2 or gPALB2 mutations from statistical analysis, HR
mutations were recorded in 6 out of 14 responders (OR
42.9%, CI 21.4-67.4) contrasting none of the 13 non-
responders (OR 0%, CI 0.0-22.8, P ¼ 0.02, Table 2).
Among patients not harboring HR mutations, 6 out of 8
olaparib responders were found methylated at the BRCA1
promoter (OR 75.0%, CI 40.9-92.9), contrasting 3 out of 13
non-responders (OR 23.1%, CI 8.2-50.3, P ¼ 0.03, Table 2).
Taken together, pathogenic HR mutation (germline or so-
matic) and/or BRCA1 promoter methylation was observed in
16 out of 18 responders (OR 88.9%, CI 67.2-96.9), contrasting
4 out of 14 non-responders (OR 28.6%, CI 11.7-54.7, P ¼
0.0008). Apart from two patients carrying somatic mutations
in the MEN1 and PTEN gene, BRCA1 methylation and HR
mutations (germline or somatic) were mutually exclusive
(Figure 2 and supplementary Table S4, available at https://
doi.org/10.1016/j.annonc2020.11.009). Notably, no tumor
harbored BRCA1 methylation and a germline/somatic BRCA1
mutation in concert (Figure 2 and supplementary Table S4,
available at https://doi.org/10.1016/j.annonc2020.11.009).
Somatic HR mutations observed in the primary biopsies
disappeared after treatment in four patients (#5-8, Figure 2).
The most likely explanation for this was a low tumor cell
fraction after olaparib response (see supplementary Results,
available at https://doi.org/10.1016/j.annonc2020.11.009).
Interestingly, the only tumor where a HR mutation appeared
after treatment (PALB2) was an olaparib non-responder (#25)
harboring a germline BRCA1 mutation. Further, the onlyVolume xxx - Issue xxx - 2020
H. P. Eikesdal et al. Annals of Oncologytumor (#23) with a change in BRCA1methylation status (gain
of BRCA1 methylation post-treatment) was also an olaparib
non-responder (Figure 2).
In addition to HR mutation and BRCA1 methylation an-
alyses, we determined downstream functional (‘phenotyp-
ical’) HR deficiency by an MLPA-based BRCAness analysis of
copy number variation (CNV) to identify tumors with a
BRCA1-like profile.36 However, no statistically significant
association between the MLPA-based BRCAness signature
and response to olaparib was observed (P ¼ 0.07; Table 2
and supplementary Table S3, available at https://doi.org/
10.1016/j.annonc2020.11.009).
An overview of all mutations recorded by targeted
sequencing of the 360-gene panel before and after olaparib
monotherapy is given in supplementary Table S5 and as an
oncoplot in supplementary Figure S4 (available at https://doi.
org/10.1016/j.annonc2020.11.009). Besides HR mutations,
we observed mutations in genes associated with other types
of DNA damage repair (DDR), like ERCC2 (germline), MSH6,
MUTYH (germline) and PARP10. Except for a gMUTYH muta-
tion found in a patient not responding to olaparib (stable
disease; SD), all DDRmutationswere observed in concert with
either an HR mutation or BRCA1methylation (supplementary
Table S4, available at https://doi.org/10.1016/j.annonc202
0.11.009), questioning their biological relevance to olaparib
outcome. Further, neither TP53 mutations (supplementary
Table S4, available at https://doi.org/10.1016/j.annonc202
0.11.009) nor total mutational load (supplementary
Table S6, available at https://doi.org/10.1016/j.annonc202
0.11.009) predicted response to olaparib. Notably, while
olaparib reduced the total number of mutations in the
responder group (P ¼ 0.01), no reduction was recorded
among non-responders (supplementary Table S6, available at
https://doi.org/10.1016/j.annonc2020.11.009).
To expand on the pre-planned HRD analyses outlined
above, a set of post-hoc analyses were carried out on
pretreatment samples. Functional HR deficiency, as defined
by low RAD51 scores,37 correlated to HR mutations/BRCA1
methylation status (supplementary Table S7, available at
https://doi.org/10.1016/j.annonc2020.11.009), as well as
olaparib response (supplementary Figure S5 and Table S8,
available at https://doi.org/10.1016/j.annonc2020.11.009).
In contrast, no correlation was observed between BRCA1
foci scores and olaparib response (supplementary Figure S5
and Table S4, available at https://doi.org/10.1016/j.
annonc2020.11.009). Finally, PAM50 gene expression anal-
ysis revealed 14 out of 18 olaparib responders versus 8 out
of 14 non-responders expressed a basal-like subtype (P ¼
0.3; Figure 2 and supplementary Table S7, available at
https://doi.org/10.1016/j.annonc2020.11.009). While there
was no significant correlation between a basal-like subtype
and BRCA1 methylation/BRCA1 mutations (P ¼ 0.1) or
BRCA1 methylation/HR mutations (P ¼ 0.1), four out of four
patients harboring BRCA1 mutations revealed a basal-like
subtype (supplementary Table S7, available at https://doi.
org/10.1016/j.annonc2020.11.009).
While we observed no clear correlation between stromal
or intratumoral TIL scores and HR mutations (somatic orVolume xxx - Issue xxx - 2020germline) or BRCA1 methylation status (supplementary
Table S9 and supplementary Figure S6, available at
https://doi.org/10.1016/j.annonc2020.11.009), pretreat-
ment TIL counts were higher among olaparib responders
compared with non-responders (supplementary Table S9
and supplementary Figure S7, available at https://doi.
org/10.1016/j.annonc2020.11.009). Similarly, despite no
association between PD-L1 expression in immune cells or
tumor cells and HRD parameters (supplementary Table S9
and supplementary Figure S6, available at https://doi.
org/10.1016/j.annonc2020.11.009), we observed a signifi-
cant correlation between PD-L1 expression in both immune
cells and tumor cells and response to olaparib
(supplementary Table S9 and supplementary Figure S7,
available at https://doi.org/10.1016/j.annonc2020.11.009).
Chemotherapy regimens administered after olaparib and
surgical outcomes after completed primary treatment are
summarized in supplementary Figure S8 (available at
https://doi.org/10.1016/j.annonc2020.11.009) and are not
the focus of the current report. However, a key finding was
the lack of pathological complete response (pCR) to ola-
parib monotherapy without subsequent chemotherapy, or
to olaparib monotherapy followed by olaparib at a reduced
dose (150 mg b.i.d. day 1-3 each carboplatin week) in
concert with a low-dose carboplatin regimen (AUC2 qW; 3
out of 4 weeks per month). This caused a protocol
amendment mandating more potent chemotherapy regi-
mens without PARP inhibition after the initial 10 weeks of
olaparib (see supplementary Methods, available at https://
doi.org/10.1016/j.annonc2020.11.009).DISCUSSION
Previous studies have revealed the benefit of PARP inhibitors
for gBRCA1/2 mutation carriers across breast, ovarian,
pancreatic and prostate cancer.15,16,19-21,25,38,39 While the
efficacy of olaparib in patients with advanced prostate and
ovarian cancer extends beyond gBRCA1/2 mutations,21,24,25
olaparib was ineffective in patients with late-stage, meta-
static TNBC not harboring gBRCA mutations.17 Here, we
present results from a phase II trial demonstrating a 56.3%
objective response rate for olaparib monotherapy in patients
with treatment-naïve, unselected primary TNBC and a 51.9%
response rate among patients not harboring gBRCA1/2 or
gPALB2 mutations. Of note, acquired resistance to platinum
agents is associated with secondary mutations restoring HR
function,22,23,40 and may promote PARP inhibitor resis-
tance.12,41 Thus, prior exposure to DNA crosslinking agents
such as platinum and probably cyclophosphamide may
explain the discrepancy between our results in treatment-
naïve patients and the negative finding observed previously
in late-stage metastatic breast cancer.17
Similar to what was recorded in advanced prostate can-
cer,24 we find somatic defects in HR to predict response to
olaparib in primary TNBC. Combining HR mutations and
BRCA1 promoter methylation assessment, we identified HR
defects in 16 out of 18 olaparib responders, contrasting 4
out of 14 non-responders. Of note, somatic BRCA1https://doi.org/10.1016/j.annonc.2020.11.009 7
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in our cohort, confirming recent findings in a population-
based study of 237 patients with TNBC.11 If a combined
analysis of HR mutations and BRCA1 methylation was used
as a selection biomarker to start PARP inhibition, 16 out of
20 patients selected for olaparib monotherapy in our trial
would have obtained an OR. While these findings need
confirmation in larger studies, they indicate a potential for
HR mutations and BRCA1 methylation as predictive markers
identifying treatment-naïve TNBCs likely to benefit from
PARP inhibitor monotherapy.
Notably, different genomic signatures for HRD or BRCA-
ness have been tested as potential predictive markers for
platinum or PARP inhibitor sensitivity, revealing conflicting
results.12,26,36,42 Here, 69% of TNBC harbored a basal-like
subtype by PAM50 analysis, but the basal-like subtype
was not enriched among olaparib responders. Also, using
MLPA analysis, we found the BRCA1-like signature not to be
predictive of response to olaparib in the current patient
cohort. Although we lack a definite explanation for this
finding, an HRD signature could remain as a genomic ‘scar’
in the tumor’s mutational and/or copy number profile,
despite tumor cells regaining HR function from secondary
reverting BRCA or RAD51C/D mutations.13,26,43 However,
while such secondary mutations have been detected in
tumors developing acquired chemoresistance,13,43 they are
less likely to be present in treatment-naïve patients.
Furthermore, while we observed no correlation between
BRCA1 foci and response to olaparib, a similar lack of cor-
relation between BRCA1 expression and platinum sensitivity
was previously established for advanced TNBC.26 A potential
explanation for this is inactivation of other key HR-related
genes causing HRD44 despite normal BRCA1 expression.
Regarding the single non-responder harboring a germline
BRCA1 mutation, this patient harbored a pathogenic mu-
tation within a region of BRCA1 previously shown to be
potentially removed by alternative splicing,37,45 thus
rescuing BRCA1 function. The pretreatment biopsy however
revealed a low RAD51 foci score, indicating definite HR
deficiency at the time the patient commenced on olaparib.
In contrast, while three non-responders revealed BRCA1
hypermethylation, two of these tumors expressed a high
RAD51 score, indicating lack of effective BRCA1 silencing.
For the last non-responder, BRCA1 methylation and a low
RAD51 score were observed in the pretreatment breast
biopsy, and olaparib yielded profound regression of the
breast primary tumor. Still, according to the RECIST criteria
this patient’s response to olaparib was classified as pro-
gressive disease due to the appearance of an axillary
metastasis on MRI, suggesting that HR-proficient tumor cell
subclones in the breast may have metastasized to the axilla
during PARP inhibitor treatment.46
Our findings indicate that olaparib monotherapy can be
used in the neoadjuvant setting for TNBC to debulk large HR
deficient tumors before implementing chemotherapy. Of
note, while talazoparib monotherapy yielded a higher pCR
rate in gBRCA mutation carriers20 than we observed for
sequential olaparib and chemotherapy in patients with8 https://doi.org/10.1016/j.annonc.2020.11.009unselected TNBC, the two trials are not directly comparable.
In the talazoparib study patients received PARPi treatment
for a longer duration. Both studies enrolled a limited
number of patients, and the fraction of patients diagnosed
with stage III disease, a factor predicting for a lower pCR in
the neoadjuvant setting,47 was higher in our study than in
the talazoparib trial (72% versus 15%, respectively).20 At the
same time, our results demonstrate that PARP inhibition
alone or followed by combined low-dose carboplatin and
PARPi, may not be a substitute for established and effective
chemotherapy regimens in TNBC.10,30,48 Identifying the
optimal chemotherapy regimen, potentially including
immunotherapy, for patients with TNBC is an area of
intensive research; yet, the results are at variance.6,49,50 In
the current TNBC cohort we observed that tumors
responding to olaparib were characterized by high TIL and
PD-L1 expression levels, a subset where immunotherapy
may be of particular benefit.6,50 Based on our post-hoc
results showing higher TIL and PD-L1 expression levels in
olaparib responders, we advocate further testing of olaparib
in concert with chemotherapy and potentially immuno-
therapy in sequential neoadjuvant regimens for TNBCs
harboring HR mutations or BRCA1 methylation. Notably, a
recent Early Breast Cancer Trialists’ Collaborative Group
meta-analysis demonstrated sequential administration of
chemotherapy to be at least as effective as concomitant
administration of the same compounds in primary breast
cancer,3 indirectly providing a rationale for sequential
treatment approaches where PARPi may be tested as initial
monotherapy before optimal chemotherapy regimens.
While gBRCA1 mutations and BRCA1 methylations are
strongly associated with TNBCs, gBRCA2 mutations are
distributed across different breast cancer subtypes, mirroring
spontaneous tumors. Also, in the TCGA dataset, somatic
mutations affecting different HR genes are observed in all
breast cancer subtypes (https://www.cancer.gov/tcga). These
findings suggest that PARP inhibition may be of potential
benefit in a wider selection of patients with breast cancer.
Finally, the findings that PARP inhibitor monotherapy may
work in breast and prostatic carcinomas harboring somatic
HR mutations24 indicate that PARPi may be effective in other
types of cancer with HR deficiency as well.Conclusion
Olaparib monotherapy yielded a high response rate when
administered to treatment-nai€ve, large TNBC, with germline
or somatic HR deficiency. While the benefit of PARP inhib-
itor monotherapy in TNBC needs confirmation, it presents a
potential sequential approach for TNBC downstaging before
chemotherapy.
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